Cg Oncology company information, Employees & Contact Information

CG Oncology Completes Rapid Enrollment in Phase 3 Study for Intermediate-Risk Non-Muscle Invasive Bladder Cancer Quiver Quantitative

CG Oncology Brings Breakthrough Bladder Cancer Treatment to Goldman Sachs Healthcare Conference Stock Titan

Enrollment goal met in PIVOT-006 trial of cretostimogene grenadenorepvec in IR-NMIBC Urology Times

CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment Nasdaq

CG Oncology to Present at Upcoming Investor Conferences in September 2025 Quiver Quantitative

41.8% Complete Response: CG Oncology's Breakthrough Bladder Cancer Drug Shows Best-in-Disease Durability Stock Titan

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals The Manila Times

Cretostimogene yields high CR rate in BCG-unresponsive NMIBC Urology Times

CG Oncology Announces Pricing of Public Offering for 8 Million Shares of Common Stock at $28 Per Share Nasdaq

CG Oncology Announces Pricing of Upsized Initial Public Offering Business Wire

Largest-Ever Trial: 360 Patients Join CG Oncology's Breakthrough Bladder Cancer Study One Year Early Stock Titan

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC Urology Times

CG Oncology Reports Strong Durability Data for Cretostimogene Grenadenorepvec and Positive Legal Outcome in Recent Press Release | CGON Stock News Quiver Quantitative

CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug Stock Titan

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire

CG Oncology Wins Legal Victory Against ANI Pharmaceuticals in Royalty Dispute Quiver Quantitative

Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC Urology Times

Cretostimogene grenadenorepvec made available through expanded access program Urology Times

Study launches of cretostimogene grenadenorepvec in NMIBC Urology Times

Phase 3 trial of oncolytic immunotherapy in NMIBC hits enrollment goal Urology Times

FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC Urology Times

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial Yahoo Finance

Why Cg Oncology Stock Rocketed 7% Higher Today The Motley Fool

FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC OncLive

CG Oncology (CGON) Reports Promising Results In BOND-003 Trial Yahoo Finance

BOND-003 Study of Cretostimogene Grenadenorepvec in NMIBC Completes Enrollment Targeted Oncology

Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating Yahoo Finance

From Challenge to Change: Addressing Unmet Needs in Bladder Cancer Treatment Fierce Healthcare

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? (NASDAQ:CGON) Seeking Alpha

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer Reuters

CG Oncology’s bladder cancer drug gets fast track to approval Pharmaceutical Technology

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC OncLive

Stocks Flashing Renewed Technical Strength: CG Oncology Investor's Business Daily

FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec Pharmaceutical Executive

CG follows big IPO with new results for bladder cancer drug BioPharma Dive

CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech BioPharma Dive

CG Oncology Completes Enrollment for Phase 3 Study Orange County Business Journal

Protara, CG Oncology Tout Promising Bladder Cancer Outcomes BioSpace

A First Take On CG Oncology (NASDAQ:CGON) Seeking Alpha

In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M Fierce Biotech

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade) (NASDAQ:CGON) Seeking Alpha

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene (NASDAQ:CGON) Seeking Alpha

CG Oncology Bringing Undervalued Innovation To Bladder Cancer (NASDAQ:CGON) Seeking Alpha

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M Genetic Engineering and Biotechnology News

CG Oncology’s Upsized $380M IPO is First Biotech to Go Public in 2024 BioSpace

CGON Stock Price and Chart — NASDAQ:CGON TradingView

CG Oncology CEO highlights biotech’s oncolytic immunotherapy for bladder cancer MedCity News

Drugmaker CG Oncology Grabs $47 Million for Bladder Cancer Trials The Wall Street Journal

Oncolytic immunotherapy biotech CG Oncology nabs $47M round for late-stage cancer push Fierce Biotech